Echo IQ’s FDA-cleared cardiac AI is moving from validation to commercial scale, with Pro Medicus distribution and a A$4.69 probability-weighted five-year value creating asymmetric upside.
Overview
Echo IQ Limited (ASX: EIQ) is an early-commercial medical AI company that automates detection of structural heart disease from structured echocardiographic measurements. Its EchoSolv AS algorithm is FDA-cleared for aortic stenosis, while EchoSolv HF is under FDA 510(k) review for heart-failure detection. The platform is differentiated by near-instantaneous output, low cloud-processing requirements, and clinical performance of 100% accuracy for severe aortic stenosis phenotypes and 99.5% sensitivity for heart failure versus approximately 50% human-review accuracy. The company charges USD 150–250+ per analyzed scan or enters multi-year enterprise licenses. **Commercial momentum is accelerating:** EchoSolv processed more than 10,200 scans in the June 2026 quarter, up 20% sequentially and more than 400% year over year. Distribution through Pro Medicus’s Visage 7 and the Mayo Clinic Platform could materially reduce hospital-integration friction. Financially, EIQ remains pre-revenue, with FY25 revenue of A$91,000 and a net loss of A$13.3 million, but the July A$110 million placement and initial A$10 million Pro Medicus note lifted pro-forma cash above A$123 million. Boutique analyst consensus is Strong Buy with 12-month targets of A$1.90–A$1.95. The key near-term catalyst is FDA clearance for EchoSolv HF.